The association of CD4, a glycoprotein involved in T cell development and antigen recognition, and CCR5, a chemotactic G protein-coupled receptor, which regulates trafficking and effector functions of immune cells, forms the main receptor for the human immunodeficiency virus HIV. We observed that the vast majority of CCR5 is maintained within the intracellular compartments of primary T lymphocytes and in a monocytic cell line, contrasting with its relative low density at the cell surface. The CCR5-CD4 association, which occurs in the endoplasmic reticulum, enhanced CCR5 export to the plasma membrane in a concentrationdependent manner, whereas inhibition of endogenous CD4 with small interfering RNAs decreased cell surface expression of endogenous CCR5. This effect was specific for CCR5, as CD4 did not affect cell distribution of CXCR4, the other HIV co-receptor.
Introduction
The CC chemokine receptor 5 (CCR5) is a seven membrane-spanning domain, G protein-coupled receptor (GPCR), which regulates chemotaxis and effector functions of T-lymphocytes, macrophages, and dendritic cells (reviewed in ). Upon activation by its cognate 1 chemokines, CCL5 (former Regulated upon Activation, Normal T cell Expressed and Secreted, RANTES), CCL3 and CCL4 (former macrophage inflammatory proteins 1 and 1 ) , CCR5 leads to cellular signaling through G proteins as well as G protein-independent α β 2 3
pathways . In addition to its physiological functions, CCR5 is also the main coreceptor of the human immunodeficiency virus (HIV), in 4 association with CD4 , a cell-surface glycoprotein that participates in molecular complexes involved in both T cell development and 5
antigen recognition by T cells. CD4 is a single-membrane spanning domain receptor interacting with class II major histocompatibility complex molecules and with its cognate ligand IL-16. So far, no specific physiological function has been attributed to the CCR5-CD4 6
complex.
In the context of immune cell chemotaxis , recent studies have shown that the sustained (hours) lymphocyte motility within in vivo lymph nodes, is driven by the lymphoid chemokine-rich environment and mediated by the activation of chemokine receptors . 7 Paradoxically, studies in reconstituted models have shown that stimulated chemokine receptors, including CCR5, are rapidly desensitized (seconds to minutes) via phosphorylation and -arrestin translocation before being internalized and eventually degraded , . In fact, an β 1 8-10 adaptive mechanism to escape inactivation and maintain prolonged reactivity upon sustained stimulation has been reported for in vivo other GPGRs, based on the retention of important stocks of functional receptors within intracellular compartments (reviewed in ).
11
Initially described for protease-activated receptors (such as the thrombin receptor ), this phenomenon was subsequently reported for 12 dopamine D1 receptors in tubular renal cells , and for -opioid receptors in neurons . The list of GPCRs displaying a predominant 13 δ 14 intracellular localization is rapidly growing . A common feature for most of these prevalently intracellular GPCRs is their capacity of 11
interacting with a vast array of membrane-associated or cytoplasmic proteins that facilitate their translocation to the cell surface . Often, 15
these proteins possess their own functions, in addition to aiding GPCR expression at the cell surface . Among them, type-I 11 single-transmembrane domain proteins with a large N-terminal extracellular domain and a short C-terminus are particularly frequent. This group includes Receptor-activity-modifying-proteins (RAMPs), which facilitate cell surface expression of a Class-B GPCRs ; the 16 2 14 Cell lines and transfections THP-1 cells were a kind gift from Philip Strange lab (Reading, UK). Cell culture media were from GIBCO and chemicals from SIGMA unless otherwise specified. CHO-K1 cells were cultured in F12 medium, HeLa P4R5 in Dulbecco modified minimal essential medium (DMEM) and THP-1 cells in RPMI 1640, in an atmosphere of 5 CO . Media were supplemented with 10 fetal bovine serum % 2 % (FBS), 100 U/ml Penicillin and 100 g/ml Streptomycin. Transfections of CHO-K1 and HeLa P4R5 cells were performed using μ GeneJuice-Transfection Reagent (Novagen).
Plasmid expression constructs
Constructs for BRET experiments were described previously . Briefly, CCR5 and CXCR4 coding regions were amplified from their 21
respective cDNAs using appropriate sense and antisense primers, containing unique Hind III or Bam H1 sites, respectively. The fragments were then subcloned in frame between the Hind III and Bam H1 sites of a plasmid for YFP (Clontech) or for a humanized form of Renilla Luciferase (Biosignal; PerkinElmer Life Sciences). The plasmid for CCR5 Cter-YFP was obtained by the amplification of a shorter Δ fragment (corresponding to met1-gly301 CCR5) using a more proximal antisense primer. For CD4-Luc and CD4-YFP constructs, the stop codon of the CD4 sequence was suppressed and replaced by a restriction site using site directed mutagenesis (QuickChange site-directed mutagenesis kit, Stratagene). The coding regions of all constructs were entirely sequenced. The GABABR1-YFP and OBR-YFP constructs were kind gifts from Michel Bouvier (Montreal, Canada) and Ralf Jockers (Paris, France), respectively. The constructs for GFP-tagged wild-type VPU and phosphorylation mutant VPU were kind gifts from Florence Margottin (Paris, France). The plasmid for 2/6 22 ER-DsRed was purchased from Clontech BD Biosciences.
Antibodies
Mouse monoclonal antibodies were as follows: 2D7 anti-human CCR5 (555991, BD Pharmingen) directed against the second extracellular loop of CCR5, OKT4 anti-human CD4 (for FACS and immunofluorescence, 140048, eBioscience), 12G5 anti-CXCR4 (ab 21555, Abcam), 1F6 anti-human CD4 (for immunoblot experiments, NCL-L-CD4-1F6, Novocastra), anti-GFP (11-814-460-001, Roche).
Rat monoclonal antibodies were as follows: 1/85a Alexa-Fluor 647-conjugated anti-human CCR5 (313712, Biolegend), which recognizes 
+

Human T lymphocyte preparation and activation
Human T-cells were isolated from the peripheral blood of healthy volunteers by Ficoll density gradient centrifugation, followed by negative depletion on magnetic beads (Human T lymphocyte Enrichment set-DM, Becton Dickinson). T-cells were activated by incubation for 48 hours with anti-CD3 and anti-CD28 antibody-coated beads (Dynabeads Human CD3/CD28 T Cell Expander Kit, Invitrogen), at a bead-to-cell ratio of 1:3, in RPMI 1640 medium supplemented with pooled human AB serum and antibiotics.
FACS analysis
The proportion of surface CCR5, and CD4 on resting or activated T lymphocytes, THP-1 cells and CHO-K1 cells expressing exogenous receptors was determined by analyzing in parallel, intact and permeabilized cells. For total staining, 1 10 cells were fixed in 1
paraformaldehyde for 20 min, washed with PBS and permeabilized for 1h at 4 C in PBS, containing 2 FBS and 0,2 Triton-X-100, as %°% % described . Cells were then incubated on ice for 1h in 100 l of PBS, 2 FBS with the 1/85a Alexa Fluor 647-conjugated anti-human 24 μ % CCR5 antibody (1:50) or the OKT4 anti-human CD4 (1:100) and control isotypes at the same dilutions. For CD4, this step was followed by 1h incubation with Cy5-conjugated anti-mouse IgG (1:100). For extracellular staining, cells were incubated on ice for 1h with PBS, 2%
FBS without Triton-X-100 and subsequently incubated with the appropriate antibodies, as above. After washing with PBS, cells were fixed in 2 paraformaldheyde and processed on a Cytomycs FC500 FACS analyzer (Beckman Coulter).
%
To study the impact of CD4 co-expression on CCR5 targeting at the cell surface, CHO-K1 cells were co-transfected with plasmids coding for CCR5-Luc (at fixed concentration) and CD4-YFP (at increasing concentrations). 36h after transfection, cells were incubated on ice for 1h with 0.5 g/ml of the 2D7 anti-human CCR5 antibody, followed by incubation with Cy5-conjugated anti-mouse IgG (1:100). To determine the effect of CD4 co-expression on CXCR4 targeting at the cell surface, CHO-K1 were co-transfected with plasmids coding for CXCR4-Luc (at fixed concentration) and CD4-YFP (at increasing concentrations). FACS experiments were conducted, as described above for CCR5, by incubating cells for 1h with 0.5 g/ml 12G5 anti-human CXCR4 antibody, followed by incubation with μ Cy5-conjugated anti-mouse IgG (1:100).
The level of endogenous CCR5 at the cell surface of THP-1 cells after CD4 silencing was measured with the 1/85a Alexa Fluor 647-conjugated anti-CCR5 antibody as described above. The proportion of surface CCR5 was evaluated by analyzing both intact and permeabilized cells.
For each analysis, 10000 cells were sorted and the data analyzed using the Cytomics RXP software.
Immunofluorescence
CHO-K1 cells were seeded on glass cover slips in six-well plates (2 10 per well), transfected with the indicated plasmids, and All images were obtained using a confocal Leica DMIRE2 microsccope and analyzed using the Metamorph 7 software.
Immunoprecipitation and immunoblotting
Cells growing in 100mm dishes were lysed in 50mM HEPES, pH 7.4, 250mM NaCl, 2mM EDTA, 0.5 NP40, 10 glycerol, 0.5
deoxycholic acid (lysis buffer), containing Complete protease inhibitors (Roche), on ice for 1h. After centrifugation at 13000 g for
20min, the supernatant was collected and protein concentration determined (BCA protein assay, Pierce). Supernatants were incubated with anti-GFP antibody (2 g) for 3h at 4 C and then incubated with protein G-Sepharose beads for 1h at 4 C. After centrifugation, the μ°°i mmuno-bead-bound material was washed three times with lysis buffer. The immunoprecipitates were resolved in 10 SDS-PAGE gels.
%
After transfer on nitrocellulose, blots were probed with the appropriate antibodies, all used at 1:1000 dilution. Immunoblots were revealed by luminescence (ECL, Amersham Bioscience).
ERK activation studies
CHO-K1 grown in 6-well plates were transfected with the plasmid encoding CCR5-Luc with or without the plasmid for CD4-YFP.
After overnight starvation, cells were detached with EDTA 10mM in PBS, centrifuged (1400 g for 5 min) and resuspended in Hank ) and analyzed for ERK activation as described . Briefly, after resuspension in ice-cold 50 mM Tris-HCl pH 6.8, containing 2.5 mM 26 orthovanadate, 2.5 mM EDTA and a cocktail of protease inhibitors, cells were lysed in 2X Laemmli sample buffer. Proteins were denatured (5min at 95 C) separated by 10 SDS-PAGE and transferred on nitrocellulose membranes. Membranes were probed with°% Phospho-p44/42 MAP kinase or MAP kinase 1-2 antibodies and autoradiograms quantified using the Image J 1.38X software.
BRET assays
CHO-K1 cells (5 10 per well of a 6-well plates) were transfected with 30ng of plasmid DNA coding for the BRET donor (CD4-Luc) under the same experimental conditions. For better readability, results were expressed in milli-BRET units (mBRET), 1 mBRET corresponding to the BRET ratio multiplied by 1000. BRET ratios were plotted as a function of (YFP-YFP )/YFP / Rluc/Rluc , where
inserm-00346678, version 1 -17 Dec 2008 4 14 YFP is the fluorescence signal at 530nm after excitation at 485 nm, and Rluc the signal at 485 nm after addition of coelenterazine h. YFP 0 and Rluc correspond to the same values in cells expressing the Rluc fusion protein alone. In some experiments, cells were incubated 14h 0 before the BRET assay with Brefeldin A at 2 g/ml. 72h, resuspended and transfected again using the same protocol. Assays were conducted 7 days after the first transfection. For RNA interference experiments on human T cells, 4 10 freshly purified T lymphocytes were transfected using the AMAXA nucleofector
system, in Amaxa solution T (program U14) with 1 M of S1 and S3 oligonucleotides, as indicated above. After nucleofection, cells were μ cultured in RPMI medium supplemented with 10 FBS, antibiotics and Interleukin-7 (5ng/ml) for 72h and then activated for 48h with % anti-CD3 and anti-CD28 antibody-coated beads as described above.
Statistical Analysis
Data are expressed as a mean value SEM. Data were analyzed by using Student s t test and p < 0.05 was considered statistically ± '
significant.
Results
CCR5 is predominantly retained within intracellular compartments
To determine the cellular distribution of CCR5, both purified T lymphocytes from healthy donors and cells of the human THP-1 monocytic cell line, expressing endogenous CCR5 were analysed by FACS ( , and Sup. Table 1 ). In freshly prepared Figure 1A unstimulated T lymphocytes, the proportion of surface CCR5 was very low, 95 of total receptors being intracellular, as measured by ≈ % fluorescence analysis of intact or permeabilized cells with a CCR5-specific antibody. As shown in previous studies , surface CCR5 27 increased after stimulation with anti-CD3 and anti-CD28 antibodies (from 5 to 11 ). In THP-1 cells, CCR5 was also principally % ≈ % present within intracellular compartments, with about 90 of the receptor being found within internal compartments. These observations % were obtained with 2 different antibodies recognizing distinct epitopes (Sup. Table 1 ). The same procedure was used to measure in parallel the distribution of the CD4 molecule. As expected, in both T lymphocytes and monocytes, CD4 was predominantly expressed at the cell surface (up to 92 in activated T lymphocytes). To confirm these findings, immunofluorescence confocal microscopy studies were % conducted on the same cells subjected (P) or not (NP) to membrane permeabilization ( ). Whereas the CD4 staining was Figure 1B comparable in permeabilized and non-permeabilized cells, the major proportion of CCR5 appeared to be intracellular in both T lymphocytes and THP-1 cells. The Jurkat T cell line, which does not express CCR5, was used as negative control for staining. Colocalization studies were also conducted and demonstrated that endogenous CCR5 colocalized with both Golgi (Giantin) end ER (Bip) markers in THP-1 cells, although additional subcellular localizations cannot be excluded. CCR5 distribution was finally analyzed in transiently transfected CHO cells, which will be used in this study as a reconstitution model. As found for the endogenous receptor in T lymphocytes and THP-1 cells, in CHO cells exogenous CCR5 was predominantly intracellular under our experimental conditions, whether wild-type receptor, or a form tagged at the C-terminus with a yellow variant of the green fluorescent protein (YFP), were expressed (Sup. 
CCR5 and CD4 associate in the ER
As indicated in the introduction, the cell surface expression of many predominantly intracellular GPCRs can be markedly enhanced by the association with other proteins, which interact with the receptors in the ER and/or the Golgi apparatus, and remain associated with them, once the receptors have reached the cell surface , . We thus investigated whether CD4, in addition to its proper immunological 11 15 functions, might also interact with CCR5 in the ER and facilitate its export to the cell surface. For this purpose, we made use of a natural mutant of CCR5, lacking its C-terminal intracellular tail , that is completely retained in the ER , as supported by the complete absence 28 29 of cell-surface detection by antibodies in immunofluorescence and FACS experiments ( ). CHO cells were transiently Figure 2A ,B transfected with a construct encoding CD4, in addition to plasmids for either wild type or truncated CCR5, harbouring a N-terminal HA epitope and a C-terminal YFP (HA-CCR5-YFP and HA-CCR5 Cter-YFP constructs, respectively). In these cells, similar amounts of CD4 Δ were co-immunoprecipitated with both the full length and truncated forms of CCR5 ( ) and both HA-CCR5 Cter-YFP and Figure 2D Δ HA-CCR5-YFP colocalized with CD4 within intracellular compartments ( ). We confirmed that the CD4-CCR5 association in Figure 2C CHO cells, evidenced by co-IP studies, was not due to non-specific hydrophobic interaction, by showing that mixing cell-lysates expressing either molecule did not allow co-immunoprecipitation (Supp. Figure 3) . CD4 CCR5 interaction was further examined in live Figure 2E distance of donor and acceptor , explaining why maximal BRET values were different in wild-type CCR5 and the truncated mutant. In 30 contrast, the value of the YFP:Luc ratio, for which half-maximal BRET was obtained, was comparable, indicating that these two forms of CCR5 display the same propensity to associate with CD4. Free YFP and the GABABR1 receptor fused to YFP (GABABR1-YFP) were used as negative controls. Although GABABR1 is constitutively retained in the ER like HA-CCR5 Cter-YFP, only a weak 31 Δ non-saturable interaction with CD4-Luc could be measured. Finally, in the presence of free YFP, only a linear non-specific BRET signal was obtained. Bystander BRET signals may occur upon random collisions in cells expressing non-physiological high levels of BRET pairs . To rule out this possibility, we verified that the levels of BRET donor and acceptor proteins at BRET saturating concentration were 30 comparable or below those of endogenous CD4 and CCR5 in human monocytic THP-1 cells (Sup. Figure 4) . To confirm that the measured BRET signals are a result of interactions occurring in the ER, cells were pre-treated with brefeldin A (BFA), a drug, which induces Golgi apparatus disassembly and redistribution of Golgi-derived vesicles to the ER. The Golgi apparatus was indeed dismantled after BFA treatment ( ), and FACS analysis could not detect almost any surface receptor in cells expressing HA-CCR5-YFP ( ). Figure 3A Figure 3B
Despite these effects, BRET values remained comparable whether or not cells were treated with BFA ( ). Together, these data are Figure 3C consistent with the hypothesis that CCR5 and CD4 associate within intracellular compartments, likely in the ER, before they are exported to the cell surface.
Association with CD4 in the ER enhances CCR5 export to the cell surface
We next examined whether CD4 might enhance the proportion of surface CCR5 in a reconstituted CHO-K1 cell model. A fixed concentration of a plasmid coding for luciferase-tagged CCR5 (CCR5-Luc) was co-transfected with increasing amounts of a CD4-YFP construct. Surface CCR5 values, measured by FACS with an anti-CCR5 antibody in cells co-expressing CD4-YFP, were plotted as a function of the CD4-YFP-associated fluorescence (
). In co-transfected cells, surface CCR5 progressively increased with increasing Figure 4 levels of CD4-YFP to reach a maximum, corresponding to an augmentation of more than 100 , and then returned gradually to basal % values for higher levels of CD4-YFP ( ). The descending portion of the curve was not due to a decreased number of CD4 Figure 4B molecules that could reach the cell surface, since in the same cells, surface CD4 increased linearly with increasing amounts of total CD4-YFP (Sup. Figure 4B ). Throughout the experiments we verified that the amount of CCR5-Luc remained constant by measuring luciferase-associated activity. In control experiments, with either free YFP or with the single transmembrane domain leptin receptor fused to YFP (OBR-YFP), no enhancement of surface CCR5 was observed ( ). As for BRET experiments, the effect of CD4 on Figure 4A and B surface CCR5 expression was achieved at physiological concentrations of the two proteins (Sup. Figure 4A) . HIV can use a second chemokine co-receptor, in conjunction with CD4, to infect target cells . This receptor, CXCR4, also displays a predominant intracellular 32 distribution in human T lymphocytes and THP-1 monocytes (reference and data not shown) and can form stable complexes with CD4, 33 which are detectable by co-immunoprecipitation experiments ( and ). However, contrasting with what was observed for Figure 4C 34 CCR5, its surface expression was not positively modulated by CD4 in transfected cells ( ). Figure 4D The functional significance of the enhancement of surface CCR5, due to the presence of CD4, was estimated by measuring ERK1-2 activation. CHO cells expressing identical amounts of CCR5-Luc, determined by comparing luciferase activity, and a concentration of CD4-YFP corresponding to its maximal effect on CCR5 export, were stimulated or not with non-saturating concentrations of MIP-1 for β increasing periods of time up to 10 min ( ). The maximal activation of the MAP kinase doubled in cells co-expressing CD4 and, in Figure 5 addition, it was also reached much faster (compare lanes 3 (time 1min) in and corresponding histograms in ).
=
Figure 5A
Figure 5B
We next examined whether the effect of CD4 on CCR5 surface targeting also occurs in cells expressing endogenous receptors. We reasoned that a substantial decrease of CD4 molecules in these cells might affect the density of CCR5 at the cell surface. A panel of 3 interfering RNAs (siRNAs) was used, which targeted the CD4 sequence. THP-1 cells were submitted to 2 consecutive nucleofections and tested after a week to achieve sufficient inhibition of CD4 synthesis and decay of CCR5 molecules already present at the cell surface before the effect of siRNAs. A significant reduction of 70 80 of total CD4 was obtained with 2 specific siRNAs, compared to the control -% ( ). In the cells showing reduced CD4, surface CCR5 was significantly decreased by 25 50 , compared to the control and to Figure 6A hypothesis that CD4 molecules can modulate the proportion of surface CCR5 in cells expressing both molecules. In a physiopathological context, the HIV-1-encoded Vpu protein was reported to induce rapid degradation of CD4 shortly after its synthesis via the 35 ER-associated protein degradation pathway . In line with our findings above, the specific targeting of CD4 molecules to the proteasome 36 by overexpressed Vpu should affect the surface expression of CCR5. A stable Hela cell line, expressing both CCR5 and CD4, was transiently transfected with either wild type GFP-tagged Vpu or a GFP-fused mutant Vpu that has lost its capacity of down-regulating CD4 or free GFP (Sup ). After transfection, surface expression of CCR5 was quantified by FACS in cells expressing comparable 36 Figure 6 levels of green fluorescence. Confirming the hypothesis, expression of Vpu-GFP induced comparable and significant reduction of both total CD4 and surface CCR5, whereas the control mutant Vpu was ineffective.
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Finally, the contribution of CD4 to the cell surface expression of CCR5 was explored in primary human cells. T cells were purified from PBMCs, nucleofected with appropriate siRNAs, activated to enhance the cell surface expression of CCR5 and analyzed for both total CD4 content and proportion of cell surface CCR5 ( ). In line with the results obtained with THP-1 cells, for all 3 tested donors, Figure 6E the siRNA-mediated reduction of CD4 was associated with a decreased proportion of CCR5 at the cell surface compared to the control, ranging from 30 to 65 . Primary monocytes purified from one donor were also examined with the same assay and displayed a 75 % % reduction in the proportion of surface CCR5 (not shown).
Discussion
Although previously unreported, the predominant intracellular localization observed here for CCR5 was described for other GPCRs and might constitute a more general feature than previously appreciated. receptors can be recruited from cytosolic stores to the plasma membrane upon agonist activation of cell surface receptors or via atrial 13 natriuretic peptide-dependent heterologous activation . Interestingly, the cell surface targeting of dopamine D1 receptors is also 45 regulated via the interaction with DRIP78, a putative two-transmembrane domain protein, resident of the ER, which binds to a FXXXFXXXF motif found in the C-terminus of the receptor . The potential link between signal-mediated export of dopamine D1 46 receptors and interaction with DRIP78 has not been established yet. Nevertheless, DRIP78 is an example of an emerging paradigm in the field, namely that GPCR translocation to the plasma membrane from intracellular compartments often requires their interaction with non-conventional chaperones and escorts proteins. In addition to classical chaperones, such as calnexin, calreticulin and Bip, which regulate folding and export of proteins engaged in the secretory pathway , a vast array of membrane-associated or cytoplasmic proteins 47 has been identified, which interact with GPCRs within intracellular compartments and facilitate their cell surface expression. The list of these proteins, which also include RAMPs, RTPs, REEP, MRAP, and M10 MHC class-I molecules, already mentioned in the introduction, is rapidly growing . Based on the data reported in the present study the CD4 molecule may be a new member of this list. 11
CCR5-CD4 association has been known for a long time, as these molecules combine to form a receptor for HIV at the cell surface of mononuclear blood cells . Although still a matter of debate, studies based on different experimental approaches have suggested the 5 existence of a physical, constitutive, virus-independent, CCR5-CD4 association at the cell surface of both transfected , and primary 34 48 cells , . The association of HIV co-receptors is likely mediated by interactions involving the extracellular globular domain of CD4 and 49 50
the extracellular regions of CCR5 , , , but it has not yet been determined whether these interactions occur once the HIV co-receptors 34 48 51 have reached the plasma membrane or if they are established within intracellular compartments before their export to the cell surface. Our data strongly support the hypothesis that CCR5-CD4 interaction occurs within intracellular compartments, likely in the ER.
Facilitating the export of CCR5 to the cell surface is clearly not the principal biological function of CD4 and it is possible that the surface expression of CCR5 is enhanced by the interaction with other proteins, which eventually interact with CCR5 along the biosynthetic inserm-00346678, version 1 -17 Dec 2008 7 14 pathway. In addition, it remains to be established whether CCR5 might also be rapidly mobilized by cell signalling events, as for the dopaminergic and opioid receptors mentioned above. From a mechanistic point of view, CD4-CCR5 association in the ER might facilitate further interactions with components of the biosynthetic pathway, likely via the carboxyterminal tail of CCR5. Indeed, although not involved in the interaction with CD4, the CCR5 tail was reported to contain a bipartite motif critical for CCR5 cell surface expression , 52
and we confirmed that the CCR5 Cter mutant was completely retained within intracellular compartments, even in the presence of excess Δ CD4 (not shown). Interestingly, the effect of CD4 on surface CCR5 was concentration-dependent, displaying a bell-shaped pattern comparable to that observed for calnexin and the ER-membrane-associated protein, DRIP78 on the maturation and trafficking of dopaminergic receptors , . The existence of an optimal concentration of chaperones or escort proteins likely reflects the requirement of 46 53 a specific stoichiometry between these proteins, the receptors, and other components of the biosynthetic machinery. In the case of CD4, an alternative possible explanation may be that, at high concentrations, CD4 itself can saturate the export machinery.
For many years, no functional explanation was proposed of how HIV may have selected a composite receptor to infect human immune cells. Recently, a plausible explanation for the formation of the second major HIV receptor, constituted by CD4 and CXCR4 on T lymphocytes, came from the observation that CXCR4 associates with the T cell receptor to signal in T cells . Thus, the stable proximity 54 of CXCR4 and CD4 at the cell surface of lymphocytes likely arises from the bridging of these proteins via a common interactor, the T cell receptor. Interestingly, based on our findings, a different explanation emerges for CCR5: the physiological constitutive association of CCR5 and CD4 in the ER of blood mononuclear cells, and the subsequent translocation of the resulting complexes at the plasma membrane might be promoted by the escort properties of CD4 for CCR5.
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